To the Editor Drs Brennan and Shrank1 raised several important questions regarding the imperative of balancing individual and societal benefits of certain new medications against their large financial expense. Equitable return on investment is commonly deemed acceptable; however, defining a reasonable standard for return on investment requires appropriate and complete information.
Green JB. Costs of New Treatments for Hepatitis C Infection. JAMA. 2014;312(20):2168. doi:10.1001/jama.2014.14343